Vanda rises as nausea drug shows promise for GLP-1 side effects

Vanda Pharmaceuticals

18/11/2025 09:47

** Shares of drugmaker Vanda Pharmaceuticals VNDA.O rise 7% to $4.71 premarket

** Co says its experimental drug tradipitant significantly reduces nausea and vomiting in people taking the popular weight-loss drug Wegovy, according to results from a new clinical trial

** Study met main goal, 29.3% on tradipitant vomited vs 58.6% on placebo; also reduced severe nausea - VNDA

** Co says late-stage trial planned for 2026

** GLP-1 market exceeds $50 bln globally; tradipitant could boost adherence - VNDA

** Up to last close, stock down ~8% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))